Download PDF Open All

Salbutamol

Bronchodilator 

Sympathomimetic

 

PCP: Bronchospasm

ACP: Adjunctive management of hyperkalemia

 

  • Known hypersensitivity to salbutamol
  • Hemodynamically significant tachycardia

PCP: Bronchospasm 

  • 5 mg nebulized. Repeat doses back to back as necessary.
  • NB: nebulized medication therapy not authorized during Covid.
  • 4 x 100 mcg via metered dose inhaler.  Repeat as required. 

ACP: Adjunctive management of hyperkalemia 

  • 10-20 mg via nebulizer.  May require multiple doses back-to-back to reach total dose. 
  • NB: nebulized medication therapy not authorized during Covid.

 

Follow weight-based dosing

PCP: Bronchospasm

  • Via nebulizer
    • Age < 1 year: 2.5 mg
    • Age > 1 year: 5 mg 
    • NB: nebulized medication therapy not authorized during Covid
  • Via metered dose inhaler:
    • < 10 kg: not indicated
    • < 20 kg: 5 x 100 mcg per round.  May repeat up to 3 times.
    • > 20 kg: 10 x 100 mcg per round.  May repeat up to 3 times.

 

Salbutamol is a selective beta-2 adrenergic agonist that produces bronchodilation and some degree of vasodilation.  Some beta-1 effects can be seen, particularly at higher doses.

Inhaled:

  • Onset: 5 minutes
  • Peak: 1.5-2 hours
  • Half-life: 3.8 hours
  • Duration: 3-8 hours

 

  • Restlessness, weakness, vertigo, apprehensiveness
  • Nausea and vomiting
  • Tachycardia or other dysrhythmias
  • Paradoxical worsening of respiratory distress
  • Cough
  • Pulmonary edema
  • Sweating, pallor, flushing
  • Tremors

Discontinue administration if signs of toxicity are developing: heart rates > 150/minute in adults (> 200/minute in children), or if severe tremors, or ventricular arrhythmias develop.

Are you sure you want to sign out?

Sign Out Cancel

loading